SAVARA INC (SVRA) Stock News

NASDAQ:SVRA - Nasdaq - US8051111016 - Common Stock - Currency: USD

2.41 +0.12 (+5.24%)

Premarket: 2.4 -0.01 (-0.41%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SVRA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Savara Inc.

Savara Announces New Employment Inducement Grant

17 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

22 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

23 days ago - By: ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

25 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA

a month ago - By: ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA

2 months ago - By: Benzinga - Mentions: SBUX CRM S GEV

This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

2 months ago - By: Benzinga

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

2 months ago - By: Savara Inc.

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

2 months ago - By: Savara Inc.

Savara Announces New Employment Inducement Grant

2 months ago - By: Savara Inc.

Savara Announces Participation in Jefferies Global Healthcare Conference

2 months ago - By: Yahoo Finance

Savara Inc. (SVRA): Analysts See 212% Upside Potential

2 months ago - By: Savara Inc.

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

2 months ago - By: Savara Inc.

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

2 months ago - By: Savara Inc.

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

3 months ago - By: Savara Inc.

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

3 months ago - By: Savara Inc.

Savara Announces New Employment Inducement Grant

4 months ago - By: Savara Inc.

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

4 months ago - By: Savara Inc.

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

4 months ago - By: Savara Inc.

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

4 months ago - By: Savara Inc.

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)